Full Fiscal Year Pharmaceutical Software and Services Up 9.1%;
Earnings per share $0.29, up 27.5% over prior year
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2016 Earnings Release and Conference Call
Conference Call to be on Friday, November 11, at 4:15 PM ET
Simulations Plus Joins European SimInhale Consortium
EU Framework Programme (Horizon 2020) for Acceleration of New Inhaled Medicines
Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2016
Company Reports Record Fourth-Quarter and Full-Year Revenues
Simulations Plus Releases PKPlus™ Version 1.0
Next-generation software for preclinical and clinical trial data analysis
Simulations Plus Releases ADMET Predictor™ Version 8.0
Major upgrade includes fresh interface, additional capabilities
Simulations Plus Reports Third Quarter FY2016 Financial Results
Record quarterly revenue, 9moFY16 diluted EPS increased 23% to a record $0.242 from $0.196
Simulations Plus Sets Date for 3rd Quarter 2016 Earnings Release and Conference Call
Conference Call to be on Thursday, July 14, at 4:15 PM ET
Simulations Plus Releases DDDPlus Version 5.0
Release adds significant enhancements to unique software product
Simulations Plus Reports Second Quarter FY2016 Financial Results
Record second quarter as revenues grow 12.9%, net income up 18%
Simulations Plus Sets Date for 2nd Quarter 2016 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 13, at 4:15 PM ET
Simulations Plus Signs 5-year Consulting Agreement with Major Research Foundation
Project provides ~$4.7 million over 5 years to implement a platform for global teams engaged in model-based drug development
Simulations Plus Releases KIWI Version 1.5
A new modeling visualization experience